search button

Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old

  • Authors:
    • Yanfeng Liu
    • Haibo Liu
    • Hausheng Liu
    • Pengcheng He
    • Jing Li
    • Xin Liu
    • Limei Chen
    • Mengchang Wang
    • Jiejing Xi
    • Huaiyu Wang
    • Haitao Zhang
    • Ying Zhu
    • Wei Zhu
    • Jing Ning
    • Caili Guo
    • Chunhong Sun
    • Mei Zhang

  • View Affiliations

  • Published online on: November 2, 2016     https://doi.org/10.3892/ol.2016.5337
  • Pages: 5205-5210
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Individuals >65 years old account for a large proportion of cancer patients, and usually have poor prognoses due to relative weaker physiological function and lower drug tolerance. To characterize the efficacy and safety of dendritic cell (DC)‑activated cytokine‑induced killer cell (CIK)‑mediated treatment, and develop an adoptive immunotherapy for cancer patients >65 years old, a retrospective study was performed in 58 cancer sufferers who received 1-4 cycles of DC‑activated CIK (DC-CIK) treatment and evaluated the response (tumor remission rate) and toxicity (side effects to the treatment). The present results showed that DCs and CIKs could be expanded rapidly in vitro, and following co‑culture with DCs, the population of cluster of differentiation (CD) 3+, CD3+CD4+, CD3+CD8+ and CD3+CD56+ CIKs was significantly increased compared to CIKs without DC activation (P=0.044). In addition, DC‑CIK infusion produced marked clinical outcomes, resulting in an objective remission rate, overall clinical benefit rate and Karnofsky performance status of 44.83, 75.86 and 87.28±5.46%, respectively, which was significantly improved compared with prior to treatment (P<0.05). Additionally, subsequent to two cycles of this immunotherapy, several tumor marker expression levels declined, returning to the normal range. The proportion of CD3+CD4+ (P=0.017) and CD3+CD8+ (P=0.023) lymphocytes, and the population of CD4/CD8 cells (P=0.024) were also increased. In conclusion, the present study suggests that the immunotherapy mediated by DC-CIK is safe and effective for cancer patients aged >65 years.
View Figures
View References

Related Articles

Journal Cover

December-2016
Volume 12 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Liu Y, Liu H, Liu H, He P, Li J, Liu X, Chen L, Wang M, Xi J, Wang H, Wang H, et al: Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old. Oncol Lett 12: 5205-5210, 2016.
APA
Liu, Y., Liu, H., Liu, H., He, P., Li, J., Liu, X. ... Zhang, M. (2016). Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old. Oncology Letters, 12, 5205-5210. https://doi.org/10.3892/ol.2016.5337
MLA
Liu, Y., Liu, H., Liu, H., He, P., Li, J., Liu, X., Chen, L., Wang, M., Xi, J., Wang, H., Zhang, H., Zhu, Y., Zhu, W., Ning, J., Guo, C., Sun, C., Zhang, M."Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old". Oncology Letters 12.6 (2016): 5205-5210.
Chicago
Liu, Y., Liu, H., Liu, H., He, P., Li, J., Liu, X., Chen, L., Wang, M., Xi, J., Wang, H., Zhang, H., Zhu, Y., Zhu, W., Ning, J., Guo, C., Sun, C., Zhang, M."Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old". Oncology Letters 12, no. 6 (2016): 5205-5210. https://doi.org/10.3892/ol.2016.5337